Skip to main content

Table 1 Baseline characteristics in patients with Rheumatoid Arthritis

From: Gender- and age-related differences of statin use on incident dementia in patients with rheumatoid arthritis: a Nationwide population-based cohort study

  Statin non-user Statin user p ASD
N 25,764 25,764   
Age group    1.0000 0.00000
 40–49 3095 (12.01%) 3095 (12.01%)   
 50–59 9485 (36.81%) 9485 (36.81%)   
 60–69 7469 (28.99%) 7469 (28.99%)   
 70–79 4462 (17.32%) 4462 (17.32%)   
  > =80 1253 (4.86%) 1253 (4.86%)   
Sex    1.0000 0.00000
 Male 7298 (28.33%) 7298 (28.33%)   
 Female 18,466 (71.67%) 18,466 (71.67%)   
Co-morbidities
 Ischemic heart disease 6668 (25.88%) 8563 (33.24%) <.0001 0.16184
 Hypertension 13,454 (52.22%) 17,055 (66.20%) <.0001 0.28735
 Ischemic stroke 3298 (12.80%) 4531 (17.59%) <.0001 0.13367
 Diabetes mellitus 7250 (28.14%) 10,236 (39.73%) <.0001 0.24653
 Peptic ulcer 12,575 (48.81%) 12,110 (47.00%) <.0001 −0.03624
Co-medication
 Aspirin 3035 (11.78%) 6587 (25.57%) <.0001 0.35953
 Beta- blockers 5439 (21.11%) 8076 (31.35%) <.0001 0.23440
 CCBs 6820 (26.47%) 9939 (38.58%) <.0001 0.26060
 ACEI 2035 (7.90%) 3607 (14.00%) <.0001 0.19625
 ARBs 4060 (15.76%) 7321 (28.42%) <.0001 0.30876
Duration of RA (year)    1.0000 0.00000
  < 1 5402 (20.97%) 5402 (20.97%)   
 1–3 8018 (31.12%) 8018 (31.12%)   
  > 3 12,344 (47.91%) 12,344 (47.91%)   
  1. ASD absolutely standardized difference, CCBs calicum channel blockers, ACEI angiotensin converting enzyme inhibitors, ARBs angiotensin receptor blockers